Boudreault v. Chesapeake Biological Laboratories, Inc.

19 Mass. L. Rptr. 487
Massachusetts Superior Court·Decided May 25, 2005·No. No. 010443·Published

Opinion

Hamlin, Sandra L., J.

This is an action brought by the plaintiff, Gerard Boudreault (“Boudreault”), arising out of the termination of his employment by his former employer, defendant, Transkaiyotic Therapies, Inc. (“TKT”). The plaintiff alleges that improper and unlawful conduct on the part of TKT, and a third-party contractor, Chesapeake Biological Laboratories, Inc. (“CBL”) resulted in his being fired. The plaintiff brings three claims: Counts One and Three allege slander and intentional interference with contractual relations respectively, against CBL. Count Two alleges wrongful termination against TKT. CBL moves for summary judgment on Count One asserting that their communications with TKT regarding the allegations brought by CBL employees against the plaintiff were privileged, and that they did not abuse this privilege.

For the following reasons, the defendant, CBL’s, motion for summary judgment is ALLOWED.

BACKGROUND

At this summary judgment stage, the facts are reported in the light most favorable to the plaintiff. Anderson Street Associates v. City of Boston, 442 Mass. 812, 816 (2004), citing Augat, Inc. v. Liberty Mut. Ins. Co., 410 Mass. 117, 120 (1991).

TKT is a biotechnology company that develops biological products to treat diseases, and is headquartered in Cambridge, Massachusetts. CBL, located in Baltimore, Maryland, is a contract manufacturer that performed manufacturing services for TKT during the year 2000. The plaintiff was hired on or about January 31, 2000, by TKT as a contract manufacturer manager to manage TKTs relationship with its outside contract manufacturers, including CBL. His duties included serving as TKTs representative at CBL during manufacturing, and addressing issues TKT was having with CBL. As TKTs “man in the plant,” the plaintiff spent a significant portion of his time working at CBL.

Karen Kurtz (“Kurtz”), an assistant to CBL’s CEO Thomas Rice (“Rice”), testified that she complained to Rice in mid-September 2000, concerning an incident in which the plaintiff touched her in an inappropriate manner on her neck, shoulder and/or back area, which made Kurtz uncomfortable. Kurtz also reported the incident to the COO of CBL, John Botek (“Botek”), and informed the CBL executives that there were rumors concerning the plaintiff that they might want to investigate. Rice contacted Theresa Connolly, Esq. (“Connolly”), an employment lawyer at Piper Marbury Rudnick & Wolfe, LLP (“Piper Marbury”) for advice as to CBL’s proper course of conduct. Connolly advised Rice to investigate the allegations in a discreet manner because it potentially sounded in sexual harassment. The plaintiff disputes the sequence of events concerning Kurtz’s report of the alleged incident and CBL’s decision to contact Connolly.

Rice and Botek assert that they conducted an investigation and spoke with additional CBL employees. They claim that other employees disclosed other incidents of inappropriate conduct on the part of the plaintiff. One of these employees, Julie Baker Barnhill (“Barnhill”), allegedly reported that Kurtz had discussed the incident in which the plaintiff touched her inappropriately, and also that she dressed in a more conservative fashion when the plaintiff was present because she was uncomfortable with the way he looked at her. Another employee, Kenton Walker (“Walker”), allegedly reported to Botek that the plaintiff made a comment to the effect of, “Who did she * * * * to get her job?” when a female employee walked by. The plaintiff disputes that such an investigation took place, pointing out that Botek’s notes from the investigation have not been found, and that Kent Walker does not recall meeting with Rice and Botek. The plaintiff also asserts that Walker is not a credible witness.

Rice and Botek assert that based on further advice from Connolly regarding the investigation, they decided to ban the plaintiff from the premises. On or about September 15,2000, Rice and Botek telephoned William Fallon (“Fallon”), who served as the plaintiffs supervisor at TKT, as well as TKT’s Vice President of Manufacturing. They informed Fallon of the details of their investigation and of their decision to ban the plaintiff from the premises at CBL. On or about September 18, 2000, another phone call took place between TKT’s General Counsel, Michael Astrue [488]*488(“Astrue”), and CBL executives in which the CBL executives discussed the credibility of the complaints made by CBL employees. Again, the plaintiff disputes the sequence of events regarding CBL’s decision to contact Connolly, and its relation to the investigation and discussions with TKT executives.

The plaintiff met with Fallon and Astrue on September 22, 2000 and was informed that his employment was being terminated effective September 25, 2000. TKT contends that the termination was based on the fact that as the “man in the plant,” the plaintiff could no longer fulfill his duties if he was banned from the premises of CBL. The plaintiff asserts that ulterior motives existed for his termination, namely that he was preventing CBL from producing a drug, Replagal, that TKT was in a race with Genzyme to produce and distribute on the market for treatment of Fabiy’s disease in humans. The plaintiff asserts that CBL wanted him out of their plant, that the complaints of sexual harassment are groundless, and that the subsequent investigation may not have even occurred. The plaintiff emphasizes that no writing as to the investigation was found.

With regard to the production of Replagal, the plaintiff emphasizes that he was not allowed in the “fill room” where CBL thaws the concentrate, dilutes it, fills it into vials, and tests it before shipping. No clients Eire permitted in the fill room at CBL. The plaintiff requested permission to observe the process through an observation window, however CBL management does not allow clients in the manufacturing area. The plaintiff attests that there is nothing in the record to reveal whether the production process was rectified to address the problem of particulates in the June batch of vials, and that Good Manufacturing Practices (“GMPs”) were violated.

The Board of Directors at CBL decided to merge with a partner, Cangene, in late 1999. The merger was announced on or about October 30, 2000, and Can-gene conducted due diligence at CBL for the two weeks prior to the merger. The plaintiff asserts that the CBL President told him that prior management “put lipstick on a pig” when they were selling the company, and questions the sequence and decision of CBL to merge with Cangene.

The plaintiff started a company, Drug Development Research, Inc. (“DDR”), subsequent to his termination from TKT. Troy Chickering (“Chickering”), an employee of DDR, was requested by CBL executives to act as a project manager for a particular client at CBL. CBL executives claim they did not know that the plaintiff worked for DDR, but that they continued to use DDR because they saw no reason for the plaintiff to be onsite. The plaintiff states that he has been onsite at CBL and further asserts that DDR had been working with CBL on several projects until CBL found out that he owned the company. The plaintiff states that CBL eventually backed down and that he has worked onsite for them, and that he has managed Chickering the whole time he has worked for CBL.

DISCUSSION

Free access — add to your briefcase to read the full text and ask questions with AI

Boudreault v. Chesapeake Biological Laboratories, Inc., 19 Mass. L. Rptr. 487 (Mass. Ct. App. 2005).

19 Mass. L. Rptr. 487 (Boudreault v. Chesapeake Biological Laboratories, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Sheehan v. Tobin
93 N.E.2d 524 (Massachusetts Supreme Judicial Court, 1950)
Bratt v. International Business MacHines Corp.
467 N.E.2d 126 (Massachusetts Supreme Judicial Court, 1984)
LaLonde v. Eissner
539 N.E.2d 538 (Massachusetts Supreme Judicial Court, 1989)
Ezekiel v. Jones Motor Co., Inc.
372 N.E.2d 1281 (Massachusetts Supreme Judicial Court, 1978)
Community National Bank v. Dawes
340 N.E.2d 877 (Massachusetts Supreme Judicial Court, 1976)
Kourouvacilis v. General Motors Corp.
575 N.E.2d 734 (Massachusetts Supreme Judicial Court, 1991)
Foley v. Polaroid Corp.
508 N.E.2d 72 (Massachusetts Supreme Judicial Court, 1987)
Augat, Inc. v. Liberty Mutual Insurance
571 N.E.2d 357 (Massachusetts Supreme Judicial Court, 1991)
Shore v. Retailers Commercial Agency, Inc.
174 N.E.2d 376 (Massachusetts Supreme Judicial Court, 1961)
Highlands Insurance v. Aerovox Inc.
676 N.E.2d 801 (Massachusetts Supreme Judicial Court, 1997)
Ravnikar v. Bogojavlensky
782 N.E.2d 508 (Massachusetts Supreme Judicial Court, 2003)
White v. Blue Cross & Blue Shield of Massachusetts, Inc.
809 N.E.2d 1034 (Massachusetts Supreme Judicial Court, 2004)
Anderson Street Associates v. City of Boston
817 N.E.2d 759 (Massachusetts Supreme Judicial Court, 2004)